Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Astellas/Pfizer Unveil Positive Xtandi Data for Hormone-Sensitive Prostate Cancer
February 13, 2019
- Oncolys in Talks with Checkpoint Drug Makers for Telomelysin: President
February 12, 2019
- US Latuda Sales Might Fall Short as Lawsuits Weigh: Sumitomo Dainippon Chief
February 12, 2019
- Xofluza Top Seller in Japan in January: Encise Snapshot
February 12, 2019
- Mochida Seeks Label Expansion for Dinagest in Japan
February 12, 2019
- Pfizer Initiates Voluntary Recall of Exforge Generics after Discovery of Carcinogenic Substances Above Limits
February 12, 2019
- Sumitomo Dainippon, Aikomi Join Forces for Research on Medical Devices to Relieve BPSD
February 12, 2019
- Ethical Drug Sales Down 4.5% in December: Crecon
February 8, 2019
- SymBio Targets 11.8 Billion Yen Sales in 2022 under New 4-Year Biz Plan
February 8, 2019
- Torii Aims to Turn Profit in 2022, Forecasting Revenue Drop after Gilead HIV Pact Ends
February 8, 2019
- Torii to Sell Futhan to Nichi-Iko after 43% Off-Patent Price Slash
February 7, 2019
- Goichi Matsuda Named as New President of Torii
February 7, 2019
- Torii Launches Early Retirement Program as Part of Restructuring Plan
February 7, 2019
- Daiichi Sankyo’s Cancer Med Pexidartinib Gets Priority Review in US
February 7, 2019
- Kyowa Kirin Commences Japan PII Study of NHE3 Inhibitor for Hyperphosphatemia
February 7, 2019
- JCR, Teijin Launch Japan PI/PII of Regenerative Medicine Product for Cerebral Infarction
February 7, 2019
- Kyowa Kirin to Delay 100 Billion Yen Profit Goal, Plans 1st Voluntary Redundancy Program
February 6, 2019
- Kyowa Kirin Sales Slip 1.9% in 2018, but Profit Up on One-Off Factors
February 6, 2019
- Kyowa Kirin to Market Hisamitsu’s Transdermal Parkinson’s Drug
February 6, 2019
- Taiho Licenses Novel EGFR-TKI to US Firm Outside Japan
February 6, 2019
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…